Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: John Patterson who wrote (7114)	9/1/1998 11:04:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

John, relax, I think DanO is correct. Also calling back is easy to put off. I have heard the same thing and posted as much. MacKinsey is closer to exact spelling. Remember we were all talking about McKinsey Group which is another organization and that XOMA claims it had some communication problems with (MP), so she may not have know when or that survey had begun.Idea was stupid. When a dumb idea moves forward you can bet it came from the top. <g>

To: John Patterson who wrote (7114)	9/2/1998 8:34:00 AM
From: E.J. Neitz Jr	Read Replies (2) \| Respond to of 17367

John P., Read Dan O. Post--If True, Suspicion Mounts---- If that is what Ellen said in a message to Dan O.,, sounds like a technical smokescreen. The questions asked in the " so called survey" wouldnt give then a clue as to the extent of tax loss selling in the future etc. I doubt very much if Ellen will post anything here related to this--they just hope the discussion goes away. Very suspicious this occurred prior to Neuprex progress. Could even be a management led buy-out on the cheap--especially if they "have a feel" as to Neuprex success. Just suspicions here-no allegations--just sounds very suspect.